PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumorsMónica Tang, Michael Friedländer, Orla McNally et al.|Gynecologic Oncology|2019Cited by 88
Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk LociAmber A DeVries, James Nicklin, Joe Dennis et al.|JNCI Journal of the National Cancer Institute|2022Cited by 13